3 results
Approved WMOCompleted
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
Approved WMOCompleted
Primary: to assess the efficacy and safety of RenovaCell grafting combined with 311 nm UVB therapy and topical anti-inflammatory therapy for the treatment of stable non-segmental vitiligo. Secondary: to assess, satisfaction, cosmetic acceptability,…
Approved WMOCompleted
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…